Literature DB >> 16187177

Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.

Hans Orlent1, Ron A Mathot, Eric F Van Bommel, Arnold G Vulto, Solko W Schalm, Johannes T Brouwer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16187177     DOI： 10.1007/s10620-005-2941-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  11 in total

1.  Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.

Authors:  A C Tan; J T Brouwer; P Glue; R van Leusen; R H Kauffmann; S W Schalm; R A de Vries; B Vroom
Journal:  Nephrol Dial Transplant       Date:  2001-01       Impact factor: 5.992

2.  Recurrent glomerulonephritis and risk of renal allograft loss.

Authors:  Josep M Cruzado
Journal:  N Engl J Med       Date:  2002-11-07       Impact factor: 91.245

Review 3.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Risk of renal allograft loss from recurrent glomerulonephritis.

Authors:  Esther M Briganti; Graeme R Russ; John J McNeil; Robert C Atkins; Steven J Chadban
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

5.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 6.  The clinical pharmacology of ribavirin.

Authors:  P Glue
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

Authors:  Annette Bruchfeld; Karin Lindahl; Robert Schvarcz; Lars Ståhle
Journal:  Ther Drug Monit       Date:  2002-12       Impact factor: 3.681

8.  Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients.

Authors:  P Kramer; F W ten Kate; A B Bijnen; J Jeekel; W Weimar
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

Review 9.  Hepatitis C infection and the patient with end-stage renal disease.

Authors:  Fabrizio Fabrizi; F Fred Poordad; Paul Martin
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.

Authors:  R J Johnson; D R Gretch; H Yamabe; J Hart; C E Bacchi; P Hartwell; W G Couser; L Corey; M H Wener; C E Alpers
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245
View more
  1 in total

1.  Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.

Authors:  I H Y Cua; V Kwan; M Henriquez; J Kench; J George
Journal:  Gut       Date:  2006-10       Impact factor: 23.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.